U.S. Markets closed

OPKO Health invests in BioZone, acquires worldwide licenses

OPKO Health announced it made an investment in BioZone Pharmaceuticals and acquired rights to BioZone’s novel drug delivery platforms, including its QuSome technology. Under the terms of the agreements, OPKO has acquired a world-wide license for the development and commercialization of products utilizing BioZone’s proprietary drug delivery technology, including QuSomes, exclusively for OPKO in the field of ophthalmology and non-exclusive for all other therapeutic fields, subject in each case to certain excluded products. Additionally, OPKO acquired exclusive world-wide distribution rights to BioZone’s enhanced formulation of propofol that utilizes its proprietary technology to produce a clear solution.